The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
Daniel Povey, a professor who was fired by Johns Hopkins University, said he will no longer go work at Facebook after the company asked him to work as a contractor while it...Technologyread more
Pfizer's $100 billion offer to acquire British rival AstraZeneca appears driven, at least in part, by lower corporate tax rates in the United Kingdom, raising the question as to whether the U.S. tax code is broken.
As part of the deal, the New York-based drug manufacturer would engage in tax inversion, a financial maneuver in which a company buys an overseas subsidiary and then changes its corporate structure to where the mother company becomes the subsidiary of the foreign entity.
Pfizer told CNBC it's simply seeking the most "efficient" tax structure. "The transaction, if consummated, is expected to result in the combination of the two companies under a new U.K.-incorporated holding company, " Pfizer said in a statement.
To Jared Bernstein, an economist at the left-leaning Center on Budget Policy and Priorities, the deal "doesn't smell very good."
"They're renouncing their American citizenship to ... engage in tax avoidance and I think that's wrong," Bernstein told "Closing Bell " on Monday, adding Pfizer's rationale makes sense because the U.S. has a "very dysfunctional tax system."
Rep. Todd Young, R-Ind., a member of the tax-writing House Ways and Means Committee, said the entire tax code needs to be overhauled in a bipartisan way. Given the highly polarized state of politics today, though, such an undertaking is not likely to happen anytime soon, he suggested.
At the minimum, Young called for lowering the corporate tax rate and raising the research and development credit—but admitted that won't be enough to keep a company like Pfizer in the U.S.
"We need to go far further," Young said on "Closing Bell." "That's why I've been pushing ... to overhaul our entire code. Not just the corporate side, but also for small and medium-sized businesses."